MELANOMA MORBIDITY AND CAUSES OF SKIN MELANOMA ADVANCING IN THE REPUBLIC OF BASHKORTOSTAN
https://doi.org/10.24060/2076-3093-2012-0-1-40-44
Abstract
The article covers the data of skin melanoma advancing and of its prevalence rate in the Republic of Bashkortostan. Clinical cases of skin melanoma advancing among residents of the Republic of Bashkortostan are described. Treatment options of the disease are also mentioned. Causes of high skin melanoma advancing in the Republic of Bashkortostan in comparison with the subjects of Volga Federal district are considered in the article.
About the Authors
O. N. Lipatov
Bashkir State Medical University
Russian Federation
Russian Federation
O. L. Lagno
Bashkir State Medical University
Russian Federation
Russian Federation
A. M. Hanov
Bashkir State Medical University
Russian Federation
Russian Federation
K. V. Menshikov
Bashkir State Medical University
Russian Federation
Russian Federation
R. D. Atnabaev
Bashkir State Medical University
Russian Federation
Russian Federation
R. G. Fatihov
Bashkir State Medical University
Russian Federation
Russian Federation
References
1. Анисимов В.В., Вагнер Р.И., Барчук А.С. Меланома кожи: Часть 1. – СПб.: Наука, 1995. – 151 с.
2. Вагнер Р.И., Анисимов В.В., Барчук А.С. Меланома кожи: Часть 2. – СПб.: Наука, 1996. – 280 с.
3. Состояние онкологической помощи населению России в 2010 году / Под ред. В.И.Чиссова, В.В.Старинского, Г.В.Петровой – М., 2011. – 188 с.
4. Лемехов В.Г. Эпидемиология, факторы риска, скрининг меланомы кожи // Практическая онкология. – 2001. №4(8). – С. 3-11.
5. Avril M.F., Cascinelli N., Cristofolini M. Clinical diagnosis of Melanoma. – W.H.O. Melanoma Programme Publications. – Milano (Italy). 1994. – № 3. – 28 p.
6. Bishop DT, Demenais F, Goldstein A.M, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma // J Natl Cancer Inst. 2002. – Vol. 94(12). P. 894-903.
7. FitzGerald MG, Harkin DP, Silva-Arriete S, et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population // Proc Natl Acad Sci USA. 1996. – Vol. 93(16). – P. 8541-8545.
8. Kirkwood J.M., Ibrahim J.G., Sondak V.K. et al. High and low dose interferon alfa 2b in high risk melanoma: first analysis of intergroup trial E 1690/S9111/C9190 // J. Clin. Oncol. – 2000. – Vol. 18. – P. 244–258.
9. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers // J Natl Cancer Inst. 1999. – Vol. 91(15). – P. 1310-1316.
Review
For citations:
Lipatov O.N., Lagno O.L., Hanov A.M., Menshikov K.V., Atnabaev R.D., Fatihov R.G. MELANOMA MORBIDITY AND CAUSES OF SKIN MELANOMA ADVANCING IN THE REPUBLIC OF BASHKORTOSTAN. Creative surgery and oncology. 2012;(1):40-44. (In Russ.) https://doi.org/10.24060/2076-3093-2012-0-1-40-44
Views:
1712
Email this article 